recent review of cases (published in this issue of the Journal of Travel Medicine ), Buhl and Lindquist describe another 20 cases in travelers to endemic areas between the years 1992 to 2008. 10 An additional four case reports from Russia 11 and France 12 have been published. For a 30-year period, these 40 cases represent an estimated incidence of 1.3 case reports per year in Western travelers. In analyzing data with respect to Swedish travelers, Buhl and Lindquist calculated a risk of 1:400,000 visits. 10 Western travelers visit endemic regions in large numbers. Data from expatriates living in Kolkota 13 suggest the risk of acquiring symptomatic disease in short-and long-term travelers to be very low. 14 Our study was designed to estimate a risk incidence for visitors from two European countries to endemic regions. We estimated at-risk travelers using the total visits from the two countries to endemic regions, adjusting this by season of travel and proportion of travelers immunized. Immunization coverage was estimated from two travel clinics ' vaccine use supported by national total vaccines sold. We examined policy and practice in the risk assessment in the two specialist travel clinics.
Methods
The number of travelers from Switzerland and the UK to endemic areas (India, Thailand, China, Sri Lanka, Malaysia, Bangladesh, the Philippines, Vietnam, Indonesia, Nepal, Cambodia, Burma, Laos, and Papua New Guinea) 1 was extracted from the offi cial World Tourism Organization fi gures for the year 2004 15 and for UK travelers from the International Passenger Survey. 16 These data refl ect foreign arrivals and therefore are a crude estimate of visitors to these regions. The seasonal trend in travel was available for UK travelers only. Estimates of the vaccination rates in the UK and Switzerland were based on annual doses sold. Because quarterly sales data were not available, the impact of seasonal travel on the vaccine prescription practice could not be determined.
The total number of doses of JE vaccination dispensed by the distributors in the UK and Switzerland during 2004 was used to calculate the total number of individuals vaccinated. Based on records from two large travel clinics in London, UK, and Basel, Switzerland, we estimated that 72% of vaccinees received three doses of vaccine, 14% received two doses, and 14% received one dose of vaccine.
Data from clients of the two travel clinics, each seeing around 10,000 travelers annually, were analyzed to determine respective vaccination coverage of travelers to endemic regions. In Switzerland, recommendations have been aimed at (1) those who knew that they would be exposed for more than 4 weeks with at least 13 nights in rice-growing areas during the JE transmission season; (2) travelers with special risks (visiting friends and relatives; high-risk exposure shorter than 13 d) or an adventurous travel style and uncertain itinerary based on individual assessment; and (3) international organization collaborators who were likely to be exposed during one of their future assignments. In UK travelers, clinic policy was vaccine to be recommended if traveling for more than 3 months and during the peak transmission period of May to November. A detailed analysis of clients traveling to JE-endemic countries during 2004 and who used specialist travel clinics in Basel and London during that year revealed that 1,243 clients visited the Basel clinic and 4,254 clients visited the London clinic. A total of 546 (44.7%) itineraries met the Swiss vaccination recommendations, and a total of 26 (4.64%) were immunized. Of the 26 recipients (16 males), the average age was 31 years (range 21 -60 y). India was the most frequent destination, 13 followed by Thailand. 10 Of the 4,254 clients attending the London travel clinic and traveling to JE-endemic countries, 59 individuals (1.39%) were vaccinated based on their risk assessment and consent to vaccination. All travelers visited multiple countries, including Thailand (86%), Cambodia (73%), and India and/or Vietnam (68%).
Results

Overall
Discussion
While the public health importance of mass JE vaccination of the local children population in endemic areas is undisputed, 1 the majority of travelers are at a very low risk of infection by comparison. The risk of disease in tourists and expatriate residents is, however, unclear, and an individual risk assessment is required to identify those who should be vaccinated. Current policy for recommending vaccine is focused on purely theoretical risk factors for acquiring infection and traveling for longer periods in rural settings during peak transmission seasons. Based on travel data from the UK (adjusted by season of travel), this study has estimated that 42% of the 17 million European travelers (ie, 7.1 million) visit endemic countries during the peak transmission season and could be considered at risk of infection. The national vaccine sales suggest that vaccination coverage is around 1% of travelers to endemic countries (UK and Swiss). Using the lowest vaccination rate of 0.16% (UK clinic) and the highest rate of 0.3% (Swiss clinic), an estimate of between 116,000 and 152,000 Europeans visiting endemic countries would have received vaccination. This highlights that more than 99% of travelers are not vaccinated (protected).
The published literature details 40 cases for the past 30 years, an average of 1.3 cases per year. Although this is likely to be a signifi cant underestimate of cases, from underreporting and disease during travel, the risk incidence based on this crude numerator gives an overall disease risk incidence of 1.3 cases per 7.1 million European travelers. We have not added visits from North America, Australia, and New Zealand, although we have included the published case reports from these continents. A risk assessment for JE should include the incident risk of developing the disease, fi nancial cost of the vaccine, risk of adverse events of vaccination, and benefi ts of avoided disease (not infection). The factors to be considered when making the decision are listed in Table 1 .
Seventy percent of the 20 reported symptomatic cases were described in persons who had traveled 10 days to 5 weeks in endemic areas. The presentation of 35% of the 20 cases indicates that they had traveled outside the transmission season. 10 These fi gures highlight that long-term travel or expatriate status as well as classical transmission season do not correlate with the case reports.
Adverse events of the currently available vaccine range from 55% for mild local reactions to an estimated risk of 1 of 1 to 2 million for more severe neurological events. 7 The cost is signifi cant but not detailed in this study.
A reasonably priced and safe vaccine for use where JE epidemics occur may infl uence the risk perception and lower the threshold for vaccinating travelers in future. All travelers should be informed about the potential but low risk of JE as well as about both the potential and the incidence of adverse effects of the vaccine. This study suggests there is little to support the current policy of targeting the vaccine at any one group or recommending the vaccines be used generically by region. The potential benefi ts and costs of JE vaccination need to be decided by each fully informed traveler. The incident risk should now be an important consideration in the risk assessment. The use of personal protection measures with repellents, sprays and vaporizers, insecticide-treated clothing, and bed nets should be the mainstay of JE and other vector disease avoidance. 
